Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

As investors react to an ever-changing political climate, Ash Shehata from KPMG explains what factors they're paying ...

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses AD04’s development timeline and next steps towards approval for alcohol use disorder.

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...

Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...

The past few years have been a roller coaster ride for M&A in pharma and biotech. After the highs of the pandemic came ...

Ash Shehata from KPMG discusses how investors are feeling about the pharma and life sciences industry heading into 2025.

Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.

Cary Claiborne, CEO, Adial Pharmaceuticals, discusses promising results of the AD04 study in patients with Alcohol Use ...

As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices ...

Pharmaceutical companies’ direct-to-patient (DTP) programs have recently sparked conversations and criticism in fear of their ...